Enanta Pharmaceuticals, Inc. · Transaction Jul 12, 2023 · Filed Aug 13, 2023 · $1,001 to $15,000
XNAS · ENTA
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Enanta Pharmaceuticals, Inc
PHARMACEUTICAL PREPARATIONS
$12.37
Follow $ENTA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ENTA by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredWed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET · ENTA
MethodologySentiment absence reason unknown
ENTA
Enanta Pharmaceuticals, Inc
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
49/ 100
Veridion Score
Middle range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ENTA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Enanta Pharmaceuticals, Inc
PHARMACEUTICAL PREPARATIONSListed since
2013
Employees
120
Country
US
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$12.37
Last session
Day high
$12.37
Last session
Day low
$12.37
Last session
Previous close
$12.37
52W high
$16.85
-26.59% from high
52W low
$10.47
30% of range
Market cap
$360.3M
Beta
-0.05
Shares out
29.1M
Avg volume
272.8K
VWAP
$12.37
Last session
Price history computed in-house
1W
-3.66%
1M
-8.37%
3M
-9.71%
1Y
+9.47%
YTD
-21.56%
SMA 50 $13.08 · below
SMA 200 $13.46 · below
52W position 30%
ENTA overview
Related filings and maps
Public disclosures
Congress activity in ENTA
2 filers · 1 buys · 2 sells (0 labeled S (partial)) · Mar 20, 2015 to Jul 12, 2023 · House 3 / Senate 0
All available history · Latest 3 of 3 lines · Read 2026-10-08T10:20:03.516Z
Official filing ↗
Enanta Pharmaceuticals, Inc. · Transaction May 27, 2015 · Filed Jun 7, 2015 · $1,001 to $15,000
Enanta Pharmaceuticals, Inc. · Transaction Mar 20, 2015 · Filed Apr 11, 2015 · $1,001 to $15,000
Federal contracts
ENTA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ENTA in this window.
Lobbying spend
ENTA lobbying filings, year to date.
Registered lobbying filings matched to Enanta Pharmaceuticals, Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ENTA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ENTA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.